The realm of ASCC1 inhibitors comprises a varied array of chemicals, each strategically targeting specific cellular pathways to indirectly regulate the function of this intricate protein. Vorinostat, an HDAC inhibitor, serves as a pivotal modulator of gene expression, impacting ASCC1 through alterations in chromatin structure and gene regulation. This epigenetic modulation offers a nuanced approach to influence ASCC1 expression and, consequently, its functional roles within cellular processes. Bortezomib, a proteasome inhibitor, disrupts protein degradation, providing an indirect avenue to influence ASCC1 by affecting the turnover of key regulatory proteins. The PI3 kinase inhibitor LY294002 interferes with downstream signaling pathways, impacting cellular processes linked to ASCC1 function. TGF-β receptor inhibitor SB-431542 adds another layer of indirect modulation by disrupting a signaling pathway potentially linked to ASCC1's regulatory mechanisms.
Sorafenib, a multi-kinase inhibitor, and MEK inhibitor PD0325901 both influence the RAF/MEK/ERK and MAPK pathways, respectively, providing indirect means to impact ASCC1 by altering signaling cascades associated with cell proliferation and survival. HDAC inhibitor VX-11e contributes to epigenetic modulation, affecting ASCC1 expression. The multi-AGC kinase inhibitor AT13148 and mTOR inhibitor AZD8055 modulate various signaling pathways, indirectly influencing ASCC1 by affecting the activity of kinases linked to its regulatory mechanisms. MEK inhibitor Trametinib alters the MAPK pathway, and JNK inhibitor SP600125 modulates stress-activated protein kinase pathways, both providing indirect means to impact ASCC1 function. CHK1 kinase inhibitor AZD7762 influences cell cycle checkpoints, offering another layer of indirect regulation on ASCC1, particularly during cell cycle progression. This diverse array of inhibitors provides a nuanced understanding of potential regulatory mechanisms for ASCC1, offering insights for future research into its intricate role within cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor influencing gene expression. Alters chromatin structure and gene regulation, indirectly affecting ASCC1 by modulating the epigenetic landscape associated with its expression and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor disrupting protein degradation. Indirectly influences ASCC1 by affecting the turnover of key regulatory proteins, thereby modulating signaling cascades associated with the protein of interest. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3 kinase inhibitor impacting cell survival and proliferation. Indirectly affects ASCC1 through interference with downstream signaling pathways that regulate its function and contribute to cellular processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor influencing TGF-β signaling. Indirectly modulates ASCC1 by disrupting a signaling pathway that may be linked to its regulatory mechanisms. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor affecting RAF/MEK/ERK pathway. Indirectly impacts ASCC1 by altering the activity of signaling cascades related to cell proliferation and survival. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
HDAC inhibitor influencing gene expression. Indirectly affects ASCC1 through modulation of chromatin structure and gene regulation, impacting the protein's expression and function. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
mTOR inhibitor affecting protein synthesis and cell growth. Indirectly impacts ASCC1 through modulation of cellular processes linked to its function and regulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor influencing the MAPK pathway. Indirectly modulates ASCC1 by altering the activity of signaling cascades associated with cell proliferation and survival. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting stress-activated protein kinase pathways. Indirectly influences ASCC1 by modulating stress-related cellular responses, impacting its function during cellular stress conditions. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
CHK1 kinase inhibitor, impacting cell cycle checkpoints. By modulating CHK1 activity, it indirectly regulates ASCC1, influencing processes linked to its function during cell cycle progression. | ||||||